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Introduction
In the United States, lung cancers, 85% of which are non-small-cell   
lung carcinomas, are the second most common type of can-
cer and the leading cause of cancer-related death.1 A well-
documented and heavily studied risk factor for lung cancers 
is cigarette smoking.2 Tobacco usage has been shown to mir-
ror mortality rates caused by lung cancer.3 Although there 
has been observation of carcinogens from cigarette smoking 
causing damage to the lungs via direct DNA interference, the 
exact  mechanism  through  which  smoking  causes  genomic 
damage is not completely understood.4
Copy number alteration is one of the leading causes of 
the  variation  in  genomic  DNA  between  humans.5  Similar 
to  single-nucleotide  polymorphisms  (SNPs),  the  alterations 
result in repeated or deleted sequences, although, unlike SNPs 
these repetitions or deletions can code for entire genes instead 
of individual bases. There is existing evidence to suggest that 
copy number alterations have a significant effect on the body’s 
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ability to regulate and combat tumor gene expression.6 We 
have reported the effects of smoking on copy number altera-
tions,7  but  have  focused  on  probing  copy  numbers  by  the 
genomic location rather than by its biological function as a 
gene or a pathway. This study aims to incorporate more bio-
logical relevance to our study of copy number alterations by 
using  pathway  analysis.  Pathway  analysis  has  largely  been 
used as a means of testing for expression data, but the use of 
the technique to study copy number variations is novel and is 
the main motivation behind this study.
The objective of this study was to use variance compo-
nent tests on a gene set to analyze the methods through which 
smoking may cause tumorigenesis. Pack-years was chosen as 
the means of quantifying smoking habits, as it was a reliable 
measure of the total dose in the patient that accounted for both 
frequency and total time. The information is then analyzed 
using a proprietary statistical model called the Test for the 
Effect of a Gene Set with Copy Number data (TEGS-CN), 
which was adapted from our previous method, TEGS, a test-
ing procedure for a multivariate linear regression model using 
permutation and scaled X2 approximations.8
Methods
Lung cancer dataset. As reported in our previous study,7 
264  snap-frozen  tumor  samples  from  non-small-cell  lung 
cancer patients were collected from Massachusetts General 
Hospital, Boston, MA, and the National Institute of Occupa-
tional Health, Oslo, Norway. Detailed information regarding 
cigarette smoking and other demographic information was 
collected by trained research assistants following a modified 
version of the American Thoracic Society’s standard respiratory 
questionnaire. Written consent was obtained from all patients 
and the study was approved by the institutional review boards 
from Massachusetts General Hospital, the Harvard School 
of Public Health, the Norwegian Data Inspectorate, and the 
Local Regional Committee for Medical Ethics. From these 
264 subjects, genome-wide DNA copy numbers were mea-
sured using Affymetrix 250 K Nsp SNP array. From the array, 
copy numbers from a total of 262,264 probes were recorded. 
The  raw  copy  numbers  were  preprocessed  and  normalized 
using dCHIP algorithm9 with a reference panel consisting of 
blood DNA or DNA from adjacent normal tissues collected 
from lung cancer patients. The preprocessed copy numbers 
were then standardized for the analysis of TEGS-CN.
Molecular signature Pathway/Gene set database. Path-
ways were compared with the existing data curated by the Broad 
Institute Gene Set Enrichment Analysis Molecular Signatures 
Database (MSigDB) for matching and gene identification pur-
poses.10 We required a cutoff of at least 15 valid probes per gene 
pathway from our dataset in order to consider a given pathway in 
our analysis. This cutoff served as a means of avoiding excessively 
short pathways that would potentially bias our results. In total, 
of the 1892 pathways in our dataset, a total of 1814 underwent 
analysis and 78 failed to reach the cutoff threshold.
test for the effect of a gene set with copy number data. 
Model. Suppose that there are n subjects (n = 264 in the lung 
cancer dataset) and subject i has P DNA copy numbers of   
J genes, Yi1, Yi2, …, YiJ, where each gene j has pj copy number 
probes, Yij
T
ij ijpj YY = ( ) 1,, …  and  Pp j j
J
=
= ∑ 1 . In our model 
for pathway analysis of copy numbers, the outcomes indicate 
the P copy number values of the J genes in a gene set, and xi is 
an independent variable, the pack-years of cigarette smoking 
for subject i. We consider the multivariate linear model:
 
Yx ijkj ki jk ijk =+ + αβ ε ,  (1)
where  i=1,…,n,  j=1,…,J;  and  k=1,…,pj;  the  errors 
εε ε ij
T
ij ijpj = () 1,, …  are assumed to be independent across dif-
ferent subjects and follow an arbitrary distribution with mean 
0 and true covariance ∑j, which is often unknown, and ajk is 
the average copy number of probe k at gene j for those with 
x=0. As copy numbers are the read from copy number probes, 
we may use copy numbers and copy number probes inter-
changeably. Covariates can be incorporated in the model (1)   
by expanding ajk to be  α jkli l l
L
z
= ∑ 1 , where L is the number 
of covariates plus one (ie, the intercept), zil is the covariate l 
of subject i, zi1 is 1, and ajkl is the regression coefficient of the 
covariate l for the copy number k of gene j. Model (1) can be 
written in matrix notation by stacking data of n subjects and pj 
copy numbers from the gene j as:
 
YJ X jj jj jj =++ α αβ βε ε ,   (2)
where YY Y jj
T
nj
T
T
= () 1 ,, …  is an npj  ×  1 vector, ∈ ∈∈ ∈∈ ∈ j
T
j
T
nj
T = () 1 ,, … , 
JI I j
T
pj pj = ( ) ,, … ,  XI I j
T
pj np j xx = ( ) 1 ,, … ,   α α j
T
jj pj = ( ) αα 1,, … ,   
β β j
T
jj pj = ( ) ββ 1,, … .
Multi-locus copy number analysis: a variance compo-
nent score test. Testing procedure for pj copy numbers in gene j 
We have developed an algorithm termed TEGS for pathway 
analyses of multiple gene expressions from mRNA expression 
array data.8 In the following, we show how to adapt the TEGS 
to analyze copy number data. For testing the effect of cigarette 
smoking on copy numbers of a gene, the null hypothesis of 
interest is that cigarette smoking x has no association with the 
pj copy numbers of gene j in a pathway, or equivalently,
 
Hoj :. β β = 0
It has been shown that the traditional multivariate tests 
such as likelihood ratio tests have limited power because the 
number of copy numbers (ie, pj) in a pathway is large and 
copy  numbers  nearby  share  high  correlation.  To  overcome 
this problem, we resort to an empirical Bayes approach by 
assuming the regression coefficients for the gene j, βj follow an Pathway analyses of copy number profile
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arbitrary common distribution with mean 0 and variance τj. 
The resulting model (2) hence becomes a linear mixed model.11 
The null hypothesis Hoj : β β = 0 is thus equivalent to the null 
hypothesis for the variance component,
 
Hoj :. τ = 0   (3)
To test for the null (3), one can develop a score test for the 
variance components.12 Specifically, it can be shown that the 
score for variance component τj has the expression:
YJ XX YJ XX jj jj j
T
nj jj j nj jj
T
nj tr − () − () − ( )
−− − ∑∑ ∑ α αα α
11 1
,
where  ∑ ∑∑ ∑∑ ∑ nj jj diag = () ,, …   is  an  npj ×  npj  block  diagonal 
matrix. Since the second term is a constant, we use the first 
term of the score for τj to construct the test statistic, which is 
a nice quadratic form of the copy numbers Yj and involves the 
true covariance Σj:
 
QTj jj j
T
nj jj
T
nj jj j =− () − ()
−− YJ XX YJ α αα α Σ ΣΣ Σ 11 .
As the number of copy numbers in a gene, pj can be 
large, the true covariance matrix for ∈ij, Σj may not be easily 
estimated. We have shown in Huang and Lin8 that one can 
replace the true covariance matrix by a working covariance Vnj 
with the resulting test statistic for gene j:
 
Qjj jj
T
nj jj j =− () − ()
− YJ YJ α αα α VX XV j
1
j
T
nj
-1 ,  (4)
where αj can be estimated from the null model: Yj = Jjαj + ∈j. 
The null distribution of Qj has been shown to follow a mixture 
of χ2 distributions, which can be approximated with the inver-
sion of characteristic function.13 Because the number of sub-
jects (n = 264) may not be large enough relative to the number 
of copy numbers within a gene Pj, we utilize a permutation 
procedure  with  scaled  χ2  approximation14  to  calculate  the   
P value. We have shown through numerical simulations and 
real data analyses that the procedure is robust to the differ-
ent choices of working covariances, protects type I error rate 
and outperforms other methods such as gene set enrichment 
analysis (GSEA).8,10
For implementation, we regressed DNA copy numbers 
and pack-years of cigarette smoking on the covariates, includ-
ing age and gender, and the residuals of the regression models 
then became the input of our test statistic as the adjusted 
DNA copy numbers Yj and smoking pack-years Xj. This par-
tial regression technique can avoid repeated fitting null model 
in each permutation and save the computation cost.
testing procedure for P copy numbers from all J genes 
in a pathway. We have shown above that the TEGS can be 
adapted to perform joint analyses of multiple copy numbers 
in a gene j. But it requires additional development prior to 
analyzing  all  P  copy  numbers  from  J  genes  in  a  pathway. 
Model (1) can be written in matrix notation by stacking data 
of n subjects and total P copy numbers from J genes as:
  YJ X =++ α αβ β∈ ∈,
where YYY T = () 1
T
n
T ,, …  is an nP × 1 vector, YY Y i
T
i
T
iJ
T = () 1 ,, … ,   
∈ ∈∈ ∈∈ ∈ T = () 1
T
n
T ,, … ,  ∈ ∈∈ ∈∈ ∈ i
T
i
T = () 1,, … iJ
T ,  JII T = () PP ,, … , 
XI I T
PP = () xx n 1 ,, … , α αα αα α ΤΤ = ( ) 1 ,, … J
T ,  β ββ ββ β TT
J
T = ( ) 1 ,, … . 
The null hypothesis that there does not exist any association 
between the P copy numbers in the pathway and the smoking 
pack-years can be expressed as:
 
H0 : β β =0 .
We may follow the same development for the gene j by 
assuming that all elements in β follow the same arbitrary dis-
tribution with mean 0 and variance τ:
 
H0 0 :. τ =   (5)
This is a valid test, but has the disadvantage that the gene 
with more copy numbers is more likely to dominate the test. 
Therefore,  we  have  to  adjust  for  the  fact  that  genes  have 
various number of copy number probes and make the signals 
from genes with different sizes comparable. To achieve this, 
we modify the above null hypothesis as:
 
Hw jj 0 0 :, ττ == for  1, ,. j= J …   (6)
One  can  choose  different  weighting  schemes  to  up-
weight the gene with less copy numbers and down-weight the 
gene with more copy numbers. For example, wj can be the 
inverse of the number of copy number probes within gene j; or 
with equal weighting, the null reduces to the hypothesis (5). 
We propose to weight by the variability of Qj, with wj being 
the inverse of the variance for Qj.
w nj jj
T
nj nj nj jj
T
nj nj jj Q −− −− − = ( ) = ()
1 Vart r 2 11 11 VX XV VX XV Σ ΣΣ Σ , (7)
As discussed above, the estimation for the covariance 
for Pj copy numbers may not be stable. We approximated Σnj 
by only taking the diagonal component of the sample covari-
ance matrix or adding the fifth percentile of the variances to 
the diagonal elements to stabilize the covariance matrix. The 
resulting test statistic follows a similar expression as (4):
 
Q w
T
n
T
nw pathway =− () − ()
−− YJ VX XV YJ αα 11 ,  (8)
where  YY Y w
T
w
T
wn
T = () 1,, …   is  an  nP  ×  1  vector, 
  ( ) 1
12 12
1
// ,,
−− = … TT T
j wi i iJ ww YY Y . Note that Vn in (8) needs to   
be a correlation matrix rather than a covariance matrix since Huang et al
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the variance have been accounted for in the weighting scheme. 
Again, we are able to approximate the distribution of Qpathway 
through permutation and calculate the P value by comparing 
the distribution and the observed value of Qpathway. We can 
also approximate the distribution with scaled χ2 distribution 
by matching the first two moments.8 We term this new proce-
dure for copy number analyses as TEGS-CN.
Examples of working covariance Vn include (1) working 
independence, which assumes that the genes are independent 
in a gene set and (2) unstructured sample covariance. The 
unstructured sample covariance is estimated using the residuals 
obtained by performing separate simple linear regression of 
individual copy numbers on smoking pack-years in (1). When 
the total number of copy number probes in a gene set, P, is 
large and the sample size, n, is small, the standard empiri-
cal unstructured sample covariance estimator is unstable. We 
hence stabilize it using a ridge estimator by adding the fifth 
percentiles of sample variances to the diagonal of the empiri-
cal covariance estimator. Other working covariance structures 
have been compared and discussed in TEGS.8
simulation studies. To  mimic  the  real  copy  number 
data, we based our simulation on the copy number data of the 
264 lung cancer tumors. We simulated the data from a gene 
set, type 3 secretin system, which contained 22 genes and 
58 copy number probes. We then randomly selected a propor-
tion π of the 58 copy numbers to be causal copy numbers Y* 
and simulated pack-years of cigarette smoking X* according 
to a regression model:
 
Xi
* , =∈ Yi
*Tβ β + ι
∗
where i =1 264 ,, … ,  Yi
T
iJ i YY *
,
*
*,
* ,, = () 1 … , β βΤ = ( ) ββ 1,, * … J , J* is  
a rounded integer of 58π,  ( ) 0 35 9 *~ ,. i N ∈ , and for simplicity,
ββ β 1 == = … J * .
We conducted three sets of simulation studies to evalu-
ate the performance of TEGS-CN. In the first set of simula-
tion, we fixed the proportion of causal copy numbers, π to be 
0.2 and varied the magnitude of the CN-smoking association 
β from 0 to 5 (Fig. 1A). For each parameter configuration, 
we simulated 1,000 datasets, and estimated the size and the 
power of TEGS-CN as the proportion of 1000 P , 0.05. 
We studied tests using both the working independence and 
the sample correlation, and P values were calculated using 
permutation and scaled χ2 approximation. In the second set 
of simulation, we fixed the magnitude of non-zero β’s to be   
1 and varied the proportion of causal ones among the 58 copy 
numbers, π from 0 to 1 (Fig. 1B).
In the third set of simulation, we fixed the proportion 
of causal copy numbers, π, to be 0.2, similar to the first set 
of simulation. However, instead of randomly assigning the 
causal copy numbers, we assign them to smaller genes (Fig. 2). 
As a result, the proportion of causal genes was 0.36 (8 genes) 
among the 22 genes, although the proportion of causal copy 
numbers was 0.2 among the 58 probes. In this setting, we 
compared the size and the power of TEGS and TEGS-CN, 
both with working independence, to illustrate the importance 
of weighting in TEGS-CN.
results
simulation studies. The size of TEGS-CN was well 
protected at P , 0.05 under both working independence and 
unstructured sample correlation: 0.047 (0.049 using scaled χ2 
approximation) for working independence and 0.043 (0.049) 
for sample correlation. The power increased with the magni-
tude of CN-smoking association (Fig. 1A) as well as the pro-
portion of non-zero CN-smoking association (Fig. 1B). The 
statistical powers from permutation and scaled  χ2 approxi-
mation  were  very  similar.  TEGS-CN  with  working  inde-
pendence performed better when the signals were weak or 
sparse, whereas TEGS-CN with working sample correlation 
performed better when the signals were strong or dense. We 
noted that the difference between the two working correla-
tion structures is that TEGS-CN with sample correlation is 
able to borrow information from the neighbor copy number 
probes. When the CN-smoking association is weak or sparse, 
the additional information from neighbor copy numbers may 
introduce unnecessary noises rather than significant signals. 
For the genome-wide scan, we chose to use working indepen-
dence since the overall signals across the genome may not be 
strong. However, one can use sample correlation for candidate 
gene sets if strong or dense signals for certain gene sets are 
plausible assumptions.
To  illustrate  the  importance  of  weighting  in  TEGS-
CN and its novelty over the original TEGS, we compared 
their performance when the association signals are sparse but 
enriched in eight smaller genes out of the total 22 genes within 
a gene set. In Figure 2, the numerical simulation revealed that 
TEGS-CN  were  consistently  more  powerful  than  TEGS. 
Through weighting in (7), we were able to account for the 
number of copy number probes within a gene and to make the 
effects contributed from genes with different sizes comparable. 
In contrast, TEGS treated each copy number probes equally, 
which  implicitly  up-weighted  the  larger  genes  and  down-
weighted the smaller genes. Despite the different performance 
under the alternative, it is noteworthy that both TEGS-CN 
and TEGS had well-protected type I error under the null, 
0.053 (0.053 using scaled χ2 approximation) for TEGS-CN, 
and 0.058 (0.058 using approximation) for TEGS. As men-
tioned in the Methods section, both are valid tests without 
inflation of type I error under the null; however, TEGS is 
likely to be subject to bias due to various sizes of the genes 
within a gene set.
Analysis  of  cigarette  smoking  and  copy  numbers  in 
Non-small cell lung cancer (NscLc) tumor genome. As 
discussed in the Methods section, we applied our proposed 
algorithm to analyze the genome-wide copy number data of 
non-small-cell lung cancer, studying the association of copy 
number profile with cigarette smoking. The demographic and Pathway analyses of copy number profile
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clinical characteristics of 264 patients are presented in Table 1. 
We divided the total participants into 132 heavy smokers and 
132 light- or non-smokers by the median value (35.6) of the 
pack-years of cigarette smoking collected by a modified stan-
dard American Thoracic Society questionnaire.
Different pathways contain different numbers of genes 
that DNA copy numbers were measured from the array. The 
distribution of the number of genes in a pathway is shown 
in Figure 3A. The average number of genes per pathway was 
39.7,  while  the  median  was  19  (interquartile  range  (IQR): 
10–39.8). The smallest pathway was one gene long, while the 
largest (STEMCELL_NEURAL_UP) was 1201 genes long. 
Genes also contain different numbers of copy number probes: 
the largest number of probes per gene is 600 (CSMD1) and the 
smallest is 1, with average number being 8.8, median being 3, 
and IQR being 1–8. We also present the distribution of the 
number of copy number probes per pathway in Figure 3B. 
The average number of probes per pathway was 365.5, and 
the median (IQR) was 146 (60–344.8). The largest pathway 
(ALZHEIMERS_DISEASE_DN)  includes  10,060  copy 
number  probes,  whereas  the  smallest  includes  one  probe. 
The large number of genes or copy number probes and the 
modest sample size (n = 264) represented the nature of large 
P and small n for the analytic problem. Moreover, the various 
numbers of copy number probes per gene demonstrated the 
necessity of weighting the signals from different genes with 
various sizes, as the null hypothesis (6).
We utilized the TEGS-CN algorithm to investigate the 
association  of  copy  numbers  of  non-small-cell  lung  cancer 
with  the  pack-years  of  cigarette  smoking.  After  running 
the pathways through the TEGS-CN analysis tests, it was 
found that of the 1814 pathways, 53 pathways had P values 
less  than  1  ×  10−3,  14  pathways  had  P  values  less  than 
1 × 10−4, and 5 pathways were under the Bonferroni cutoff 
at 0.05/1814 = 2.8 × 10−5. Because of the large number of 
copy  number  probes  per  pathway,  we  introduced  a  work-
ing  independence  structure  to  save  computation  burden. 
Table 2 shows the top five pathways, including the PTEN 
pathway (PTENPATHWAY: P = 7.8 × 10−7), the gene set 
up-regulated  in  heat  shock  experiment  (HEATSHOCK_
YOUNG_UP: P = 3.6 × 10−6), the gene set down-regulated 
in rejection of kidney transplantation (FLECHNER_PBL_
KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN: 
P = 9.2 × 10−6), the gene set involved in transcriptional regu-
lation of leukocytes (SCHRAETS_MLL_TARGETS_UP: 
P = 2.2 ×  10−5), and the ganglioside biosynthesis pathway 
(GANGLIOSIDE_BIOSYNTHESIS: P = 2.7 × 10−5).
For the top five pathways, we further performed gene anal-
yses where we analyzed multiple copy numbers in a gene to study 
the association with cigarette smoking (Tables 3–7). Among the 
10 genes in PTENPATHWAY, the association of PTK2 copy 
numbers  with  cigarette  smoking  was  highly  significant;  the 
association of MAPK1, SOS1, and PIK3R1 were marginally sig-
nificant (P , 0.1). For the gene sets for heat shock up-regulation 
(HEATSHOCK_YOUNG_UP), DYNLL1 seemed to drive the 
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significance of the gene set. Of the 31 genes involved in kidney 
transplantation rejection, there were five significant genes with 
P , 0.05 and three marginally significant genes with P value 
between 0.05 and 0.1. Of the 21 genes involved in transcriptional 
regulation  of  leukocytes  (SCHRAETS_MLL_TARGETS_
UP), there were seven significant genes with P , 0.05. Finally, 
there were three highly significant genes out of the six involved 
in ganglioside biosynthesis.
discussion
Copy  number  alterations  have  been  reported  to  corre-
spond  to  the  majority  of  the  variation  in  gene  expression 
of tumor genome.6 There is a pressing need to understand 
copy  number  alterations  in  relation  to  phenotypic  trait 
such as cigarette smoking or clinical outcome in the con-
text of biological pathway or gene set. Thus, in this study, 
we  develop  a  new  method  for  pathway  analyses  of  copy 
number data, TEGS-CN. The method is adapted from our 
previous algorithm TEGS, a testing procedure for gene set 
or pathway analyses. Although TEGS has been developed 
for pathway analyses of gene expression data, it may not be 
readily applicable to copy number analysis due to the various 
numbers of copy number probes in genes. Without proper 
adjustment in TEGS, larger genes with more copy number 
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figure 3. Distribution of numbers of genes (A) and copy number probes (b) in pathways. note that the number of genes (A) and copy number probes (b) 
per pathway was truncated at 500 and 4000, respectively, due to skewness of the distribution, and the entire range was described in the text.
Table 1. Characteristics of the 264 non-small-cell lung cancer patients.
ToTAL hEAvY SMokERS* LIGhT- oR NoN-
SMokER*
sample size 264 132 132
male (%) 61.4 67.4 55.3
age
mean +/- sD 67.4 +/- 8.3  67.7 +/- 8.0 67.1 +/- 8.5
Cigarette smoking in Pack-Years
median +/- IQr 35.6 +/- 38.72 58.8 +/- 40.5 19.8 +/- 18.7
Clinical stage
stage 1 (%) 73.1 73.5 72.7
stage 2 (%) 17.0 15.9 18.2
stage 3 or 4 (%) 9.08 10.1 7.6
Cigarette smoking status
never smoked (%) 6.8 0 13.6
Ex-Smokers (%) 48.5 49.2 47.7
Current smokers (%) 44.7 50.8 38.6
adenocarcinoma (%) 66.3 64.4 68.2
Notes: *Heavy smokers are defined as pack-years of cigarette smoking .35.6 (the median of the smoking pack-years in 264 subjects), and light- or non-smokers 
are those with #35.6 smoking pack-years.Pathway analyses of copy number profile
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Table 2. The five pathways with P value ,0.05 after Bonferroni adjustment.
GENE PAThwAY (MSigdb Id) NUMbER of  
GENES
NUMbER of CoPY  
NUMbER PRobES
NoMINAL   
P-vALUES
PtenPatHWaY 10 54 7.8 × 10−7
HeatsHoCK_YoUnG_UP  5 21 3.6 × 10−6
fLeCHner_PBL_KIDneY_transPLant_reJeCteD_Vs_oK_Dn 31 103 9.2 × 10−6
sCHraets_mLL_tarGets_UP 21 120 2.2 × 10−5
GanGLIosIDe_BIosYntHesIs 6 37 2.7 × 10−5
 
Table 3. P values of genes in PtenPatHWaY.
GENES  woRkING  
INdEPENdENCE
SAMPLE  
CovARIANCE
PTK2 6.52 × 10−7 0.0592
SOS1 0.0391 0.0131
PIK3R1 0.0726 0.0606
MAPK1 0.0891 0.135
PIK3CA 0.106 0.106
ITGB1 0.239 0.255
CDKN1B 0.295 0.295
ILK 0.270 0.270
GRB2 0.457 1.65 × 10−4
PTEN 0.539 0.539
Table 4. P values of genes in HeatsHoCK_YoUnG_UP.
GENES woRkING  
INdEPENdENCE
SAMPLE  
CovARIANCE
DYNLL1 1.42 × 10−6 5.92 × 10−7
CHD1L 0.214 0.492
TRA2A 0.230 0.177
WDR89 0.360 0.360
ANXA1 0.767 0.404
probes may dominate the signal for the gene set and bias the 
results. Therefore, we extended the algorithm by introducing 
a general weighting scheme to make the information from 
genes with different sizes comparable. We showed in simula-
tion that with proper weighting for each copy number probes 
to  make  each  gene  comparable,  TEGS-CN  outperformed 
TEGS in terms of the statistical power (Fig. 2). The general 
weighting is not only limited to adjusting for gene size but 
can also be used to incorporate other parameters, for example, 
prior information of a gene in relation to the phenotypic trait 
of interest. Moreover, the TEGS-CN can also be used to 
analyze other genomic data such as DNA methylation array.
Our  method  (TEGS-CN)  analyzes  the  copy  number 
as a continuous measure. If either amplifications or deletions 
of copy number have a significant relation to the phenotypic 
trait, our method is able to detect the association. If one would 
like to analyze the copy number by categorizing into discrete 
classes (amplified, neutral, and deleted copy numbers), addi-
tional development is required to incorporate such a kind of 
analyses.  However,  collapsing  the  continuous  copy  num-
bers into categorical classes loses information and therefore 
decreases the statistical power. On the other hand, TEGS-CN 
is an omnibus test, which can detect if there is any effect of a 
gene set (see null hypothesis (6)) but cannot distinguish where 
the effect is and the directionality of the effect. Once identifying 
candidate gene sets or genes, one can study the dose–response 
relationship for each copy number, to further investigate which 
kind of alterations is related to the phenotype.7
The top pathways have been shown to be biologically 
significant  in  cancer.  The  PTEN  pathway,  which  gave  us 
the highest P value among all the pathways, is a well-known 
cancer-related pathway. Typically, PTEN suppresses tumors 
by inducing apoptosis in abnormal cells, but in many cancers, 
including non-small-cell lung cancer, it becomes expressed 
in  reduced  copy  numbers,  which  leads  to  excessive  cell 
proliferation.15  One  of  the  genes  expressing  high  P  values 
is  PTK2,  which  controls  cellular  adhesion  and  mobility. 
Down-regulation of this gene means less metastasis in cancer 
cells as they no longer move freely.16
The following three pathways that were discovered were 
a variety of different immunological pathways. Each relates in 
some way to different cellular functions of the human body 
that functions as anti-cancer or responses to toxic exposures 
and  organ  transplants.  The  HEATSHOCK_YOUNG_UP 
pathway  is  a  pathway  that  becomes  up-regulated  in  lym-
phocytes after heat shock in younger individuals when com-
pared with the lymphocyte reaction in older individuals. It is 
considered to be an indicator of immune response strength 
and recovery, as its regulation reflects the gradual degrada-
tion of the recuperative ability with age.17 Among the genes 
in the heat shock pathway, the one with the most significant 
P value was DYNLL1. This gene codes for a light chain in 
the protein dynein, and as such influences a wide variety of 
cellular  processes.18  The  FLECHNER_PBL_KIDNEY_
TRANSPLANT_REJECTED_VS_OK_DN  pathway  is Huang et al
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a pathway relating to immunosuppression. It has been studied 
in patient reactions to kidney transplants, principally how the 
body mounts acute rejection or has no reaction.19 Two genes 
had  particularly  strong  results  in  this  pathway.  The  gene 
ZNF148 regulates transcription of a variety of genes, one of 
which is stromelysin, a protein thought to be active in tumor 
initiation.20 SYNPO is a gene that controls synaptodin, which 
relates  to  actin  and  cell  motility.21  SCHRAETS_MLL_
TARGETS_UP  is  a  pathway  that  controls  transcriptional 
regulation of human leukocytes. Although the normal func-
tion of the pathway is not well understood, it is known that 
translocations in this pathway will result in acute leukemia.22 
ENPP2 is the autotaxin enzyme, which increases tumor cell 
motility via the creation of lysophosphatidic acid (LPA).23
GANGLIOSIDE_BIOSYNTHESIS is a pathway that 
controls the formation of gangliosides in the human body. 
Gangliosides serve as differentiating surface markers in cells, 
controlling cell growth, development, and apoptosis. It is also 
known that certain cancers result in the expression of modi-
fied gangliosides or an overall reduced expression. Two gan-
gliosides created in this pathway that appeared significant in 
our data were ST8SIA1 and ST3GAL5. ST8SIA1 codes for 
an enzyme that produces the GD3 ganglioside, a ganglioside 
known to be involved in cell adhesion and malignant growth.24 
ST3GAL5 codes for an enzyme that produces the GM3 gan-
glioside,  which  participates  in  differentiation,  morphology, 
proliferation, and adhesion.25
Table 6. P values of genes in sCHraets_mLL_tarGets_UP.
GENES woRkING  
INdEPENdENCE
SAMPLE  
CovARIANCE
MGLL 5.40 × 10−5 0.00177
RSPO2 7.98 × 10−5 0.0395
HSPB8 0.000145 9.61 × 10−5
ENPP2 0.00199 0.000263
TGFBI 0.00952 0.0954
THBS2 0.0243 0.00311
IL1RN 0.0272 0.0265
CTSH 0.0529 0.0559
CAP1 0.0869 0.106
ARHGDIB 0.161 0.171
COL6A3 0.215 0.00658
MVK 0.281 0.233
CDKN1B 0.295 0.295
GATA6 0.466 0.466
GSTA4 0.476 0.425
ACADM 0.491 0.0850
FOXC2 0.492 0.492
DFFB 0.625 0.625
LIMK1 0.686 0.686
CD53 0.775 0.405
PITX2 0.994 0.994
 
Table 5. P values of genes in fLeCHner_PBL_KIDneY_
transPLant_reJeCteD_Vs_oK_Dn.
GENES  woRkING  
INdEPENdENCE
SAMPLE  
CovARIANCE
ZNF148 9.86 × 10−5 0.245
SYNPO 0.00064 0.00064
IK 0.00588 0.00588
ANAPC13 0.0363 0.0363
SETD1A 0.0453 0.0495
MYD88 0.0519 0.0519
SFRS3 0.0733 0.0897
GOLGA1 0.0987 0.113
CD46 0.104 0.0810
STK38 0.203 0.203
RIOK3 0.206 0.1623
GSPT1 0.208 0.1477
ITGB1 0.239 0.255
LMO1 0.287 0.288
CDKN1B 0.295 0.295
SFRS2B 0.335 0.335
MAPK14 0.367 0.0444
RABGGTB 0.372 0.261
GPR56 0.381 0.187
PTGER2 0.438 0.438
GTF2B 0.438 0.438
PCBP2 0.470 0.470
TMEM63A 0.488 0.488
TRAF3IP3 0.506 0.0411
ACO2 0.524 0.548
CHAF1A 0.554 0.554
BICD2 0.555 0.576
RALBP1 0.607 0.653
TES 0.634 0.101
CTCF 0.656 0.656
TMF1 0.700 0.429
 
Table 7. P values of genes in GanGLIosIDe_BIosYntHesIs.
GENES woRkING  
INdEPENdENCE
SAMPLE  
CovARIANCE
ST3GAL1 0.000441 0.118
ST8SIA1 0.000489 0.176
ST3GAL5 0.00527 0.00578
ST3GAL4 0.0721 0.0725
ST6GALNAC2 0.402 0.316
ST3GAL2 0.740 0.740Pathway analyses of copy number profile
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